Levofloxacin

Results: 390



#Item
51P 279  EUCAST disk diffusion with pefloxacin 5 µg as screen for fluoroquinolone resistance in Salmonella spp. Variation between media, disks and testing sites Erika Matuschek1, Robert Skov2, Jenny Åhman1, Maria Karlsso

P 279 EUCAST disk diffusion with pefloxacin 5 µg as screen for fluoroquinolone resistance in Salmonella spp. Variation between media, disks and testing sites Erika Matuschek1, Robert Skov2, Jenny Åhman1, Maria Karlsso

Add to Reading List

Source URL: www.eucast.org

Language: English - Date: 2014-05-07 02:58:00
52EUCAST steering committee meeting November[removed], 2002

EUCAST steering committee meeting November[removed], 2002

Add to Reading List

Source URL: www.eucast.org

Language: English - Date: 2008-10-20 06:10:38
53Reference broth microdilution MICs from EUCAST Development Laboratory Enterobacteriaceae Mueller-Hinton (MH) broth Antimicrobial agent Ampicillin Amoxicillin

Reference broth microdilution MICs from EUCAST Development Laboratory Enterobacteriaceae Mueller-Hinton (MH) broth Antimicrobial agent Ampicillin Amoxicillin

Add to Reading List

Source URL: www.eucast.org

Language: English - Date: 2014-11-04 08:19:49
54Rationale for the EUCAST clinical breakpoints

Rationale for the EUCAST clinical breakpoints

Add to Reading List

Source URL: www.eucast.org

Language: English - Date: 2009-12-12 17:14:34
55Rationale for the EUCAST clinical breakpoints

Rationale for the EUCAST clinical breakpoints

Add to Reading List

Source URL: www.eucast.org

Language: English - Date: 2009-12-12 17:14:35
56Rationale for the EUCAST clinical breakpoints

Rationale for the EUCAST clinical breakpoints

Add to Reading List

Source URL: www.eucast.org

Language: English - Date: 2009-12-12 17:14:35
57EV-035: Novel 2-pyridone based topoisomerase inhibitors with broad-spectrum activity against MDR pathogens, including quinolone resistance F-2030 52nd ICAAC 2012

EV-035: Novel 2-pyridone based topoisomerase inhibitors with broad-spectrum activity against MDR pathogens, including quinolone resistance F-2030 52nd ICAAC 2012

Add to Reading List

Source URL: www.evolva.com

Language: English - Date: 2012-09-13 02:28:15
58Evolva-Superbugs-5Mar2012

Evolva-Superbugs-5Mar2012

Add to Reading List

Source URL: www.evolva.com

Language: English - Date: 2012-06-29 03:42:56
59The following is a list of the most commonly prescribed drugs. It represents an abbreviated version of the drug list (formulary) that is at the core of your prescription-drug benefit plan. The list is not all-inclusive a

The following is a list of the most commonly prescribed drugs. It represents an abbreviated version of the drug list (formulary) that is at the core of your prescription-drug benefit plan. The list is not all-inclusive a

Add to Reading List

Source URL: www.bannerhealth.com

Language: English - Date: 2015-02-07 23:12:31
60Rationale for the EUCAST clinical breakpoints

Rationale for the EUCAST clinical breakpoints

Add to Reading List

Source URL: www.eucast.org

Language: English - Date: 2009-12-12 17:13:00